financetom
Business
financetom
/
Business
/
Verizon's Q1: Flat Revenue, Bump In Free Cash Flow And Stable 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Verizon's Q1: Flat Revenue, Bump In Free Cash Flow And Stable 2024 Outlook
Apr 22, 2024 6:29 AM

Verizon Communications Inc ( VZ ) stock traded higher Monday after it reported fiscal first-quarter 2024 results. 

Its sales increased 0.2% year over year to $32.98 billion, marginally missing the consensus of $33.24 billion. Adjusted EPS of $1.15 beat the consensus of $1.12.

Total wireless service revenue was $19.5 billion, up 3.3% Y/Y, driven primarily by pricing actions implemented in recent quarters, higher premium price plan adoption, and growth of its fixed wireless subscriber base. Postpaid phone net losses were 68,000, and retail postpaid net additions were 253,000.

The quarter marked 389,000 total broadband net additionsThe company ended the quarter with approximately 11.1 million broadband subscribers.

Total Verizon Business revenues were $7.4 billion, down by 1.6% Y/Y.

Total Verizon Consumer revenue rose by 0.8% Y/Y to $25.1 billion. Consumer wireless retail postpaid churn was 1.03%, and wireless retail postpaid phone churn was 0.83%. 

Verizon Consumer clocked wireless retail postpaid phone net losses of 158,000. Verizon Consumer had fixed wireless net additions of 203,000.

The consumer segment EBITDA margin improved by 110 bps 42.6%, attributed to service revenue growth and lower upgrade volumes, while the business segment EBITDA margin declined 130 bps to 20.7%, driven by wireline revenue declines. 

Company-level adjusted EBITDA of $12.1 billion, up from $11.9 billion Y/Y.

Verizon Chairman and CEO Hans Vestberg. “We are on track to meet our financial guidance and to deliver positive Consumer postpaid phone net adds for the year.”

FY24 Outlook: Verizon reiterated a 2.0% – 3.5% wireless service revenue growth. It maintained an adjusted EPS of $4.50 – $4.70 versus consensus of $4.58.

Verizon stock gained over 9% in the last 12 months. Investors can gain exposure to the stock via Invesco Dow Jones Industrial Average Dividend ETF and First Trust Morningstar ETF .

Price action: VZ shares traded higher by 2.17% at $41.37 premarket on the last check Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved